ATYR aTYR PHARMA INC Insider Trading

Director Paul Schimmel buys 100,000 shares of ATYR at $0.50; stock down -94.0% from 52-week high, but up +11.1% in past month.

Director Paul Schimmel purchased 100,000 shares at $0.50 on 2026-05-27, increasing his holdings by 14.7% to 779,143 shares total. This trade occurs as ATYR shares trade at $0.44, down -94.0% from the 52-week high of $7.29 but up +11.1% over the past 30 days, suggesting recent price recovery despite the company's distressed valuation. The company is deeply unprofitable with net income of $-10,791,000.00 against minimal quarterly revenue of $190,000.00, and annual revenue has contracted -19.2% year-over-year. Schimmel's prior ATYR purchases show mixed timing: his three July 2024 buys returned +71.7%, +79.5%, and +73.4% over 90 days, but his October 2025 buys posted -20.7% and -19.3% over the same horizon. The current purchase at a depressed price point with recent upward momentum warrants scrutiny given the company's severe operational and financial deterioration.

Director SCHIMMEL PAUL bought 1,000,000 shares for $911,801.16 (blended $0.91) at aTYR after -85.6% 52-week decline

Director SCHIMMEL PAUL purchased 1,000,000 shares across 2 transactions totaling $911,801.16 at prices ($0.90 and $0.94) near the current $0.95 level, expanding his holdings by 242.1% from 413,023 to 1,413,023 shares. This substantial accumulation occurs while aTYR is trading -85.6% from its 52-week high of $6.61 and down -82.1% over the past 30 and 90 days, with the company reporting zero quarterly revenue and a negative net income of $-19,531,000.00. Notably, SCHIMMEL PAUL's prior 3 buys at aTYR (July 2024) were all well-timed at the 90-day mark, posting returns of +73.4%, +79.5%, and +71.7%, suggesting a pattern of initiating purchases during or near significant drawdowns that subsequently recovered. The current purchase signals either conviction in a recovery from depressed levels or repositioning ahead of potential strategic developments, but occurs in a company experiencing severe operational stress (-33.4% annual revenue decline and ongoing operating losses) and faces significant valuation and liquidity headwinds evident in the 52-week price trajectory.

Director Jane A. Gross bought 3,750 shares of ATYR at $4.00; holdings surge 62.5% to 9,750 shares amid unprofitable operations and -33.4% annual revenue decline.

Director Jane A. Gross purchased 3,750 shares at $4.00 on 2025-03-17, increasing her stake by 62.5% from 6,000 to 9,750 shares. The transaction occurs in the context of a company with revenue of $0.00 in the latest quarter, a net loss of $-17,259,000.00 for the full fiscal year, and annual revenue declining 33.4% year-over-year. The current stock price of $4.01 reflects a +17.6% 30-day gain and +30.2% 90-day gain, positioning the stock within 9.5% of its 52-week high of $4.43. A director's choice to substantially increase shareholdings during a period of severe profitability challenges and shrinking revenue warrants scrutiny regarding underlying business outlook or strategic developments not yet publicly reflected in near-term financials.

Director Paul Schimmel purchased 100,000 shares across 3 transactions (July 22-24) at blended avg $1.85, raising holdings 31.9% to 413.0K shares.

Paul Schimmel, a Director at aTYR Pharma, executed 3 separate purchases totaling 100,000 shares for $184,613.40 over three consecutive trading days, with transaction prices ranging from $1.74 to $1.93. This represents a 31.9% increase in his shareholding from 313,023 shares to 413.023 shares. The purchase comes as the company faces significant financial headwinds: latest-quarter revenue was only $235,000.00, the company recorded a net loss of $-15,491,000.00, and annual revenue growth contracted by -96.6% year-over-year. At the transaction time, the stock was near its 52-week high ($1.98), having risen 18.4% over the prior 30 days. However, Schimmel's cross-ticker track record shows limited predictive value: his prior buys averaged a -2.2% 30-day return and -12.9% 90-day return with a 0.00% win rate. The scale and timing of this purchase warrant attention given the company's deteriorating fundamentals and the insider's historical execution record.